| Literature DB >> 35267999 |
Véronique Bélanger1,2, Josianne Delorme1,2, Mélanie Napartuk1,2, Isabelle Bouchard2, Caroline Meloche2, Daniel Curnier2,3, Serge Sultan2,4,5, Caroline Laverdière5,6, Daniel Sinnett2,6, Valérie Marcil1,2.
Abstract
This study aims to describe the feasibility of a nutritional intervention that promotes healthy eating habits early after cancer pediatric diagnosis in patients and their parents. Participants were recruited 4 to 12 weeks after cancer diagnosis as part of the VIE study. The one-year nutritional intervention included an initial evaluation and 6 follow-up visits every 2 months with a registered dietician. The feasibility assessment included rates of retention, participation, attendance, completion of study measures, and participants' engagement. A preliminary evaluation of the intervention's impact on the participants' dietary intakes was conducted. A total of 62 participants were included in the study (51.6% male, mean age = 8.5 years, mean time since diagnosis = 13.2 weeks). The retention and attendance rates were 72.6% and 71.3%, respectively. Attendance to follow-up visits declined over time, from 83.9% to 48.9%. A majority of participants had high participation (50.8%) and high engagement (56.4%). Measures of body-mass-index or weight-for-length ratio and dietary 24-h recalls were the procedures with the highest completion rates. Participants with refractory disease or relapse were less likely to complete the intervention. Post-intervention, participants (n = 21) had a lower sodium intake compared to the initial evaluation. These results suggest that a nutritional intervention that involves patients and parents early after a pediatric cancer diagnosis is feasible.Entities:
Keywords: acute treatment phase; childhood cancer; feasibility study; nutritional intervention
Mesh:
Year: 2022 PMID: 35267999 PMCID: PMC8912879 DOI: 10.3390/nu14051024
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram of participants recruited for the nutritional intervention.
Characteristics of participants.
| Participants | |
|---|---|
| Sex, | |
| Male | 32 (51.6) |
| Female | 30 (48.4) |
| Age at recruitment, year | |
| Mean ± SD | 8.5 ± 5.1 |
| Median (min–max) | 7.4 (1.4–17.3) |
| Age category, | |
| Preschoolers (<5 y.o.) | 22 (35.5) |
| Children (5 to 12 y.o.) | 22 (35.5) |
| Adolescents (≥13 y.o.) | 18 (29.0) |
| Marital status, | |
| Married/common-law partners | 42 (79.2) |
| Separated/divorced/widower | 11 (20.8) |
| Parental education level, | |
| Unfinished high school | 2 (3.6) |
| High school | 13 (23.6) |
| College | 9 (16.4) |
| University | 31 (56.4) |
| Approximated gross family income, | |
| <$29,999 | 4 (7.8) |
| $30,000–$69,999 | 12 (23.5) |
| $70,000–$109,999 | 17 (33.3) |
| $110,000–$150,000 | 11 (21.6) |
| >$150,000 | 7 (13.7) |
| Cancer diagnosis, | |
| Leukemia 1 | 29 (46.8) |
| Lymphoma 2 | 12 (19.4) |
| Sarcoma 3 | 10 (16.1) |
| Other 4 | 11 (17.7) |
| Cancer evolution, | |
| Responders | 51 (82.3) |
| Non responders 5 | 11 (17.7) |
| BMI or W/L, z-score | |
| Mean ± SD | 0.3 ± 1.1 |
| Median (min–max) | 0.1 (−1.9–2.8) |
| Nutritional status, | |
| Normal | 47 (75.8) |
| Overweight/Obese | 15 (24.2) |
| Serum 25(OH)D, nmol/L | |
| Mean ± SD | 59.8 ± 24.4 |
| Median (min–max) | 58.2 (22.0–168.0) |
| Vitamin D status, | |
| Sufficiency | 36 (69.2) |
| Insufficiency | 13 (25.0) |
| Deficiency | 3 (5.8) |
SD: standard deviation; y.o.: years old; BMI: body mass index; W/L: weight-for-length ratio; 25(OH)D: 25-hydroxyvitamin D. 1 Leukemia diagnosis includes acute lymphoblastic leukemia (n = 26) and acute myeloid leukemia (n = 3). 2 Lymphoma diagnosis includes Hodgkin’s lymphoma (n = 2), Burkitt’s lymphoma (n = 6), anaplastic lymphoma (n = 2), diffuse large B-cell lymphoma (n = 1), and lymphoblastic lymphoma (n = 1). 3 Sarcoma diagnosis includes osteosarcoma (n = 2), rhabdomyosarcoma (n = 3), Ewing’s sarcoma (n = 4), and undifferentiated sarcoma (n = 1). 4 Other diagnosis includes Wilm’s tumor (n = 3), thymoma (n = 1), germinoma (n = 2), medulloblastoma (n = 1), hepatic rhabdoid tumor (n = 1), neuroblastoma (n = 2), and hepatoblastoma (n = 1).5 Non responders designate patients who had a relapse or refractory disease.
Feasibility data and comparison between participants retained and excluded.
| Participants | Retained | Excluded | ||
|---|---|---|---|---|
| Duration of the intervention, months | - | |||
| Mean ± SD | N/A | N/A | 4.6 ± 3.3 | |
| Median (min–max) | N/A | N/A | 4.9 (0–10.8) | |
| Time between diagnosis and initial evaluation, weeks | 0.34 | |||
| Mean ± SD | 13.2 ± 7.1 | 13.1 ± 7.7 | 13.7 ± 4.9 | |
| Median (min–max) | 11.9 (3.1–43.0) | 11.7 (3.1–43.0) | 12.4 (5.86–22.0) | |
| Engagement level 1, | <0.01 | |||
| Low | 9 (16.4) | 4 (8.9) | 5 (50.0) | |
| Moderate | 15 (27.3) | 15 (33.3) | 0 | |
| High | 31 (56.4) | 26 (57.8) | 5 (50.0) | |
| Participation in follow-up visits | ||||
| Number of follow-up visits completed, | <0.001 | |||
| Mean ± SD | 3.2 ± 1.7 | 4.0 ± 1.1 | 1.2 ± 1.2 | |
| Median (min–max) | 4.0 (0–6.0) | 4.0 (2.0–6.0) | 1.0 (0–4.0) | |
| Rate 2, % | <0.001 | |||
| Mean ± SD | 53.8 ± 27.6 | 65.9 ± 18.5 | 19.8 ± 19.5 | |
| Median (min–max) | 66.7 (0–100) | 66.7 (33.3–100) | 16.7 (0–66.7) |
The differences in feasibility parameters were assessed according to participants’ retention in the intervention using Mann-Whitney U-tests or Pearson Chi-square test. SD: standard deviation. 1 Level of engagement was determined subjectively by the RDs after one year of intervention based on the ease of scheduling follow-up appointments and the global interest towards the intervention. 2 Percentage of follow-up visits completed out of the six planned.
Figure 2Distribution of participants’ retention in the intervention based on their cancer evolution. The percentage of patients retained in the intervention and those excluded is illustrated according to participants’ cancer evolution (responders vs. non responders). Data were compared using Fisher’s exact test.
Attendance and completion rates of study measures at visits.
| Initial | 2-Month | 4-Month | 6-Month | 8-Month | 10-Month | 12-Month | All Visits | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Actual/ | 61/62 | 47/56 | 38/55 | 35/51 | 32/47 | 23/46 | 22/45 | 258/362 |
| Rate (%) | (98.4) | (83.9) | (69.1) | (68.6) | (68.0) | (50.0) | (48.9) | (71.3) |
|
| ||||||||
| Study measures | ( | ( | ( | ( | ( | ( | ( | Mean (95% CI) |
| 3-day food record | 23 (37.7) | - | - | - | - | - | - | - |
| Blood sample | 55 (90.2) | - | - | - | - | - | - | - |
| 24H-R | 53 (86.9) | 42 (89.4) | 31 (81.6) | 28 (80.0) | 27 (84.4) | 20 (87.0) | 16 (72.7) | 83.1 (78.6–87.6) |
| BMI or W/L | 61 (100) | 45 (95.7) | 35 (92.1) | 34 (97.1) | 30 (93.8) | 22 (95.7) | 19 (86.4) | 94.4 (91.0–97.8) |
| WC | 20 (32.8) | 7 (14.9) | 3 (7.9) | 3 (8.6) | 3 (9.4) | 1 (4.4) | 7 (31.8) | 15.7 (6.3–25.1) |
| MUAC | 37 (60.7) | 19 (40.4) | 14 (36.8) | 8 (22.9) | 7 (21.9) | 5 (21.7) | 9 (40.9) | 35.0 (23.6–46.4) |
| TSFT | 29 (47.5) | 18 (38.3) | 11 (29.0) | 6 (17.1) | 7 (21.9) | 4 (17.4) | 7 (31.8) | 29.0 (20.0–38.0) |
| SSFT | 23 (37.7) | 14 (29.8) | 8 (21.1) | 4 (11.4) | 6 (18.8) | 1 (4.4) | 5 (22.7) | 20.8 (11.9–29.7) |
Attendance was defined as the number of participants who attended a visit divided by the total number of potential participants. Completion rates of study measures (24H-R, BMI, WC, MUAC, TSFT, and SSFT) were calculated based on participants who attended each visit and expressed as a percentage. CI: confidence intervals; 24H-R: 24-h recall; BMI: body-mass-index; W/L: weight-for-length ratio; WC: waist-circumference; MUAC: mid-upper arm circumference; TSFT: triceps skinfold thickness; SSFT: subscapular skinfold thickness.
Participants’ characteristics according to their participation level.
| Participation Level | ||||
|---|---|---|---|---|
| Low | Moderate | High | ||
| (0–1 visit) | (2–3 Visits) | (≥4 Visits) | ||
| Sex, | 0.40 | |||
| Male | 5 (45.5) | 8 (42.1) | 19 (61.3) | |
| Female | 6 (54.5) | 11 (57.9) | 12 (38.7) | |
| Age at recruitment, year | 0.36 | |||
| Mean ± SD | 9.7 ± 5.7 | 9.4 ± 5.2 | 7.4 ± 4.9 | |
| Median (min–max) | 8.9 (2.4–17.1) | 8.8 (1.9–16.3) | 5.2 (1.3–17.1) | |
| Age category, | 0.06 | |||
| Children (<13 y.o.) | 6 (54.5) | 11 (57.9) | 26 (83.9) | |
| Adolescents (≥13 y.o.) | 5 (45.5) | 8 (42.1) | 5 (16.1) | |
| Marital status, | 0.74 | |||
| Married/common-law partners | 9 (90.0) | 12 (75.0) | 21 (77.8) | |
| Separated/divorced/widower | 1 (9.1) | 4 (25.0) | 6 (22.2) | |
| Parental education level, | 0.86 | |||
| Unfinished high school/high school | 4 (40.0) | 4 (25.0) | 7 (24.1) | |
| College | 1 (10.0) | 2 (12.5) | 6 (20.7) | |
| University | 5 (50.0) | 10 (62.5) | 16 (55.2) | |
| Mean gross family revenue, | 0.08 | |||
| <$29,999 | 1 (11.1) | 1 (7.1) | 2 (7.1) | |
| $30,000–$69,999 | 1 (11.1) | 2 (14.3) | 9 (32.1) | |
| $70,000–$109,999 | 7 (77.8) | 3 (21.4) | 7 (25.0) | |
| $110,000–$150,000 | 1 (11.1) | 4 (28.6) | 7 (25.0) | |
| >$150,000 | 0 | 4 (28.6) | 3 (10.7) | |
| Diagnosis, | 0.31 | |||
| Leukemia | 3 (27.3) | 9 (47.4) | 16 (51.6) | |
| Lymphoma | 2 (18.2) | 4 (21.1) | 6 (19.4) | |
| Sarcoma | 2 (18.2) | 5 (26.3) | 3 (9.7) | |
| Other | 4 (36.4) | 1 (5.3) | 6 (19.4) | |
| BMI or W/L, z-score | 1.00 | |||
| Mean ± SD | 0.3 ± 1.1 | 0.3 ± 1.3 | 0.3 ± 1.1 | |
| Median (min–max) | −0.1 (−1.0–2.5) | −0.1 (−1.9–2.8) | 0.1 (−1.7–2.3) | |
| Nutritional status, | 0.92 | |||
| Normal | 9 (81.8) | 14 (73.7) | 25 (80.6) | |
| Overweight/Obese | 2 (18.2) | 5 (26.3) | 7 (19.4) | |
| Cancer evolution, | 0.68 | |||
| Responders | 8 (72.7) | 16 (84.2) | 26 (83.9) | |
| Non responders 1 | 3 (27.3) | 3 (15.8) | 5 (16.1) | |
| Engagement level 2, | 0.001 | |||
| Low | 5 (71.4) | 3 (17.6) | 1 (3.2) | |
| Moderate | 0 | 7 (41.2) | 8 (25.8) | |
| High | 2 (28.6) | 7 (41.2) | 22 (71.0) | |
The participation level was determined for each participant based on the number of follow-up visits attended and defined as low (0–1 visit); moderate (2–3 visits); and high (≥4 visits). The relationships between participation level and characteristics (nominal variables) were evaluated using Pearson’s Chi-square or Fisher’s exact tests. The differences in continuous variables of participants according to their participation level were assessed using Kruskal-Wallis H-test. SD: standard deviation; y.o.: years old; BMI: body mass index; W/L: weight-for-length ratio. Leukemia diagnosis includes acute lymphoblastic leukemia (n = 25) and acute myeloid leukemia (n = 3). Lymphoma diagnosis includes Hodgkin’s lymphoma (n = 2), Burkitt’s lymphoma (n = 6), anaplastic lymphoma (n = 2), diffuse large B-cell lymphoma (n = 1), and lymphoblastic lymphoma (n = 1). Sarcoma diagnosis includes osteosarcoma (n = 2), rhabdomyosarcoma (n = 3), Ewing’s sarcoma (n = 4), and undifferentiated sarcoma (n = 1). Other diagnosis includes Wilm’s tumor (n = 3), thymoma (n = 1), germinoma (n = 2), medulloblastoma (n = 1), hepatic rhabdoid tumor (n = 1), neuroblastoma (n = 2), and hepatoblastoma (n = 1). 1 Non responders designate patients who had a relapse or refractory disease. 2 Level of engagement was determined subjectively by the RDs after one year of intervention based on the ease of scheduling appointments and the global interest towards the intervention.
Dietary intakes at initial evaluation according to participation level.
| Participation Level | ||||
|---|---|---|---|---|
| Low | Moderate | High | ||
| (0–1 Visit) | (2–3 Visits) | (≥4 Visits) | ||
| Energy | ||||
| Kcal | ||||
| Mean (min–max) | 1976 (767–3040) | 1418 (224–2698) | 1702 (9–3751) | 0.22 |
| Median (IQR) | 2077 (1696–2522) | 1452 (842–2058) | 1508 (1075–2149) | |
| Kcal/kg | ||||
| Mean (min–max) | 77.3 (19.5–194.0) | 51.4 (4.9–115.1) | 64.8 (0.4–159.5) | 0.48 |
| Median (IQR) | 48.8 (39.5–112.3) | 51.9 (27.9–74.4) | 50.5 (35.2–86.1) | |
| Fat | ||||
| g/kg | ||||
| Mean (min–max) | 3.4 (0.9–8.6) | 2.0 (0.2–4.9) | 2.7 (0–8.7) | 0.40 |
| Median (IQR) | 2.1 (1.4–4.8) | 2.0 (0.8–2.7) | 2.2 (1.0–3.4) | |
| % Energy | ||||
| Mean (min–max) | 38.4 (27.5–49.4) | 35.2 (23.6–53.3) | 35.4 (2.3–56.1) | 0.50 |
| Median (IQR) | 38.0 (36.9–39.9) | 35.1 (29.5–40.0) | 37.4 (31.0–39.5) | |
| Protein | ||||
| g/kg | ||||
| Mean (min–max) | 2.7 (0.6–7.8) | 2.1 (0.1–4.2) | 2.8 (0–7.5) | 0.66 |
| Median (IQR) | 1.6 (1.2–3.7) | 2.5 (1.0–3.1) | 2.2 (1.4–4.1) | |
| % Energy | ||||
| Mean (min–max) | 13.5 (11.4–16.1) | 15.9 (5.0–20.3) | 16.7 (1.0–22.9) | 0.02 |
| Median (IQR) | 13.3 (12.8–14.2) | 16.0 (13.9–19.1) | 18.1 (13.7–19.3) | |
| % RDA | ||||
| Mean (min–max) | 273.1 (67.0–741.9) | 218.0 (7.2–440.8) | 289.0 (0–712.1) | 0.69 |
| Median (IQR) | 184.1 (144.4–354.6) | 267.1 (107.1–325.0) | 232.4 (146.8–404.7) | |
| Dietary fiber | ||||
| Energy-adjusted (g/1000 kcal) | ||||
| Mean (min–max) | 9.8 (3.1201321.3) | 8.2 (3.4–15.0) | 7.6 (0–18.0) | 0.50 |
| Median (IQR) | 9.2 (6.6–10.8) | 7.7 (6.2–10.2) | 7.4 (5.3–9.4) | |
| % AI | ||||
| Mean (min–max) | 88.9 (12.3–283.0) | 45.1 (5.9–92.8) | 43.9 (0–107.0) | 0.05 |
| Median (IQR) | 73.6 (58.8–83.7) | 50.5 (19.8–63.6) | 41.5 (32.5–56.7) | |
| Sodium | ||||
| Energy-adjusted (mg/1000 kcal) | ||||
| Mean (min–max) | 1305.7 (423.2–1976.1) | 1373.8 (551.5–2781.3) | 1609.4 (29.9–7390.6) | 0.81 |
| Median (IQR) | 1538.4 (954.7–1695.1) | 1273.7 (1031.7–1665.3) | 1484.3 (1118.7–1591.1) | |
| % UL | ||||
| Mean (min–max) | 129.4 (63.3–224.0) | 97.9 (12.0–240.8) | 133.0 (0–313.1) | 0.20 |
| Median (IQR) | 107.9 (71.2–178.5) | 79.4 (42.9–143.8) | 123.7 (80.2–165.5) | |
| Calcium | ||||
| Energy-adjusted (mg/1000 kcal) | ||||
| Mean (min–max) | 464.5 (129.6–1016.6) | 657.5 (65.1–1392.3) | 619.1 (44.9–1175.7) | 0.34 |
| Median (IQR) | 449.7 (285.1–536.5) | 637.7 (466.3–792.4) | 665.8 (276.1–875.5) | |
| % RDA | ||||
| Mean (min–max) | 101.1 (7.7–260.4) | 92.3 (2.5–224.6) | 103.0 (0–334.3) | 0.99 |
| Median (IQR) | 71.9 (58.7–124.8) | 93.2 (46.6–120.8) | 71.9 (40.0–177.2) | |
| Vitamin C | ||||
| Energy-adjusted (mg/1000 kcal) | ||||
| Mean (min–max) | 59.2 (0–132.9) | 46.6 (1.9–161.4) | 81.3 (0.3–390.5) | 0.56 |
| Median (IQR) | 68.3 (22.8–87.3) | 29.2 (14.0–64.9) | 58.2 (25.4–99.0) | |
| % RDA | ||||
| Mean (min–max) | 329.5 (0.1–772.6) | 251.0 (4.9–1379.9) | 414.0 (0.9–2132.1) | 0.52 |
| Median (IQR) | 275.4 (154.1–403.5) | 101.7 (30.9–289.8) | 220.5 (87.8–508.0) | |
| Vitamin D | ||||
| Energy-adjusted (μg/1000 kcal) | ||||
| Mean (min–max) | 2.6 (0.0–8.8) | 3.5 (0–10.6) | 3.9 (0–13.3) | 0.22 |
| Median (IQR) | 2.0 (1.6–2.5) | 2.8 (1.1–4.3) | 4.1 (1.6–4.9) | |
| % RDA | ||||
| Mean (min–max) | 33.4 (0–105.5) | 32.8 (0–79.8) | 38.9 (0–101.0) | 0.59 |
| Median (IQR) | 31.2 (8.0–39.5) | 22.6 (11.7–48.9) | 38.7 (22.3–55.3) |
Dietary intakes were evaluated in participants at initial evaluation using a 24-h recall. Differences in dietary intakes according to participation level were assessed using Kruskal-Wallis H-tests. IQR: interquartile range (25th to 75th percentiles); RDA: Recommended Dietary Allowance; AI: Adequate intake; UL: Tolerable upper intake level.
Comparison of dietary intake at initial evaluation and post-intervention.
| Difference 1 | ||||
|---|---|---|---|---|
| Initial Evaluation | Post-Intervention | Mean (95% CI) | ||
| Energy | ||||
| Kcal | ||||
| Mean (min–max) | 1584 (9–3751) | 1822 (882–3386) | 299 (–236–833) | 0.25 |
| Median (IQR) | 1479 (1075–1900) | 1727 (1362–2071) | ||
| Kcal/kg | ||||
| Mean (min–max) | 61.4 (0.4–159.5) | 60.9 (17.9–120.4) | −0.4 (−17.2–16.4) | 0.79 |
| Median (IQR) | 51.9 (38.3–78.4) | 61.9 (41.0–78.0) | ||
| Fat | ||||
| g/kg | ||||
| Mean (min–max) | 2.7 (0–8.7) | 2.3 (0.6–5.7) | −0.5 (−1.5–0.5) | 0.73 |
| Median (IQR) | 2.2 (1.7–3.4) | 2.0 (1.3–3.1) | ||
| % Energy | ||||
| Mean (min–max) | 37.1 (2.3–56.1) | 33.2 (17.1–52.1) | −3.8 (−9.9–2.2) | 0.20 |
| Median (IQR) | 38.5 (33.6–39.5) | 28.7 (26.1–44.3) | ||
| Protein | ||||
| g/kg | ||||
| Mean (min–max) | 2.8 (0–7.5) | 2.7 (0.4–5.7) | −0.1 (−1.0–0.7) | 0.92 |
| Median (IQR) | 2.6 (1.5–3.3) | 2.6 (1.8–3.5) | ||
| % Energy | ||||
| Mean (min–max) | 16.8 (1.0–22.3) | 17.4 (9.3–42.5) | 0.6 (−3.4–4.6) | 0.87 |
| Median (IQR) | 18.9 (15.3–19.4) | 16.6 (14.2–18.9) | ||
| % RDA | ||||
| Mean (min–max) | 289.0 (0–712.1) | 281.9 (49.4–600.0) | −7.1 (−89.7–75.6) | 0.86 |
| Median (IQR) | 268.0 (165.5–346.6) | 282.1 (187.4–363.2) | ||
| Dietary fiber | ||||
| Energy–adjusted (g/1000 kcal) | ||||
| Mean (min–max) | 7.9 (0–18.0) | 7.2 (1.9–15.1) | −0.7 (−2.9–1.5) | 0.51 |
| Median (IQR) | 7.7 (5.9–9.9) | 7.4 (5.7–8.3) | ||
| % AI | ||||
| Mean (min–max) | 44.5 (0–92.8) | 48.1 (6.6–91.2) | 3.5 (−11.1–18.2) | 0.62 |
| Median (IQR) | 42.3 (32.5–57.5) | 47.9 (41.1–53.2) | ||
| Sodium | ||||
| Energy–adjusted (mg/1000 kcal) | ||||
| Mean (min–max) | 1612.5 (29.9–7390.6) | 1078.4 (727.7–1403.6) | −564.1 (−1193.1–64.9) | 0.03 |
| Median (IQR) | 1542.5 (1078.4–1665.6) | 1065.3 (950.7–1190.6) | ||
| % UL | ||||
| Mean (min–max) | 132.4 (0–313.1) | 100.1 (59.1–206.6) | −32.3 (−81.9–17.4) | 0.19 |
| Median (IQR) | 109.8 (74.9–165.5) | 93.5 (68.2–114.8) | ||
| Calcium | ||||
| Energy–adjusted (mg/1000 kcal) | ||||
| Mean (min–max) | 614.9 (44.9–969.1) | 581.2 (80.0–1520.2) | −33.7 (−181.6–114.3) | 0.64 |
| Median (IQR) | 637.7 (549.7–773.5) | 465.7 (349.2–723.7) | ||
| % RDA | ||||
| Mean (min–max) | 102.8 (0–334.3) | 96.3 (20.5–216.4) | −6.5 (−43.8–30.8) | 0.79 |
| Median (IQR) | 93.2 (64.2–109.8) | 76.1 (45.7–140.6) | ||
| Vitamin C | ||||
| Energy–adjusted (mg/1000 kcal) | ||||
| Mean (min–max) | 70.8 (0.3–390.5) | 86.8 (4.5–268.8) | 15.9 (−35.0–66.9) | 0.36 |
| Median (IQR) | 30.1 (16.4–63.5) | 63.2 (33.6–111.3) | ||
| % RDA | ||||
| Mean (min–max) | 292.1 (0.9–2132.1) | 436.0 (16.0–1307.7) | 143.9 (−80.8–368.7) | 0.08 |
| Median (IQR) | 98.1 (62.2–317.7) | 366.6 (149.5–679.9) | ||
| Vitamin D | ||||
| Energy–adjusted (μg/1000 kcal) | ||||
| Mean (min–max) | 3.7 (0–13.3) | 4.5 (0.3–33.1) | 0.7 (−2.7–4.2) | 1.00 |
| Median (IQR) | 4.0 (1.8–4.9) | 3.0 (0.9–5.1) | ||
| % RDA | ||||
| Mean (min–max) | 36.4 (0–80.4) | 47.9 (3.2–300.4) | 3.5 (−11.1–18.2) | 0.95 |
| Median (IQR) | 38.7 (20.3–53.0) | 35.3 (8.7–58.1) | ||
Dietary intakes were evaluated in 21 participants at initial evaluation and post-intervention using 24-h recalls. Differences in mean dietary intakes before and after the intervention were compared using Wilcoxon or paired-samples t-tests. IQR: interquartile range (25th to 75th percentiles); RDA: Recommended Dietary Allowance; AI: Adequate intake; UL: Tolerable upper intake level.1 The mean difference in dietary intake of the group was calculated as dietary intake post-intervention-dietary intake at initial evaluation.